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resumo 
 
 
Doença de Alzheimer (AD) é a doença neurodegenerativa mais comum 
relacionada com a idade que conduz à disfunção cognitiva e demência. A 
principal característica patológica da doença de Alzheimer é definida pela 
acumulação de beta-amilóide (Aβ), um péptido neurotóxico, derivado da 
clivagem da proteína precursora da amilóide (APP) pela beta e gama-
secretase. Embora tenha sido descrito que o prião celular (PrPC) desempenha 
um papel na patogénese da doença de Alzheimer, o seu papel ainda é pouco 
claro. Diversos estudos têm mostrado resultados contraditórios em relação à 
sua função na doença de Alzheimer. Para esclarecer esta questão, o principal 
objetivo deste estudo é investigar a influência do gene PRNP em ratinhos 
5xFAD. Os ratinhos 5xFAD exibem 5 mutações envolvidas na doença de 
Alzheimer familiar. Estes apresentam a acumulação de Aβ1-42 e um aumento 
da perda neuronal durante o envelhecimento. Para criar ratinhos bi-
transgénicos, os ratinhos 5xFAD foram cruzados com Prnp0/0 Zurich 1 
(nocaute para o prião celular). Os ratinhos transgénicos (5xFAD e 
Prnp0/05xFAD) com diferentes idades (3, 9 e 12 meses de idade) foram 
submetidos a uma bateria de testes de avaliação cognitiva e motora. Em 
seguida procedeu-se a uma avaliação bioquímica (ELISA, western blot e 
imunohistoquimica) para investigar o potencial envolvimento do PrPC na 
regulação e sinalização proteica induzida pela toxicidade da Aβ. O estudo 
revelou que os défices induzidos pela toxicidade da Aβ aparecem mais cedo 
nos ratinhos 5xFAD (9 meses de idade) do que nos Prnp0/05xFAD (12 meses 
de idade). A produção de beta amilóde revelou uma regulação dependente do 
PrPC na isoforma Aβ1−40 ao contrário da isoforma Aβ1−42. Ao contrário do 
que acontece nos ratinhos 5xFAD, não foi encontrada nenhuma sobre 
expressão das proteínas P-Fyn, Fyn e Cav-1 nos ratinhos Prnp0/05xFAD. Estes 
resultados sugerem um papel importante do PrPC na doença de Alzheimer 
como promotor do efeito tóxico dos oligómeros de beta amilóide, uma vez que 
a perda do PrPC atrasa o efeito tóxico dos oligómeros de beta amilóide. Em 
conclusão, os nossos dados apoiam o papel do PrPC como um agente 
mediador de toxicidade da Aβ na doença de Alzheimer. PrPC promove o início 
precoce da doença de Alzheimer. 
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abstract 
 
Alzheimer’s disease (AD) is the most prevalent age-related neurodegenerative 
disease that leads to cognitive impairment and dementia. The major defined 
pathological hallmark of AD is the accumulation of amyloid beta (Aβ), a 
neurotoxic peptide, derived from beta and gamma-secretase cleavage of the 
amyloid precursor protein (APP). It has been described that cellular prion 
protein (PrPC) plays a role in the pathogenesis of Alzheimer disease. Although, 
the role of PrPC is still unclear, previous studies showed contradictious results. 
To elucidate this issue, the main objective of the present study is to investigate 
the influence of a knockout of the PRNP gene in 5XFAD mice, 5xFAD mice 
exhibited 5 mutations related to familial Alzheimer disease. These mice show 
an Aβ1-42 accumulation and an increased neuronal loss during aging. To 
create a bi-transgenic 5xFAD mice were crossed with Prnp0/0 Zurich 1 mice 
(prion protein knockout mice). We subjected two transgenic mice (5xFAD and 
Prnp0/05xFAD) at different ages (3, 9 and 12 months of age) to a battery of task 
to evaluate cognitive and motoric deficits and a biochemical analysis (ELISA, 
western blot and immunohistochemistry) to investigate the regulation and 
potential involvement of downstream signaling proteins in the Aβ induced 
toxicity process dependent of the PrPC concentration. The study revealed that 
the deficits induced by Aβ mediated toxicity appeared earlier in 5xFAD mice (9 
months of age) than in Prnp0/05xFAD (12 months of age). Investigating the 
amount of amyloid beta in 5xFAD mice we observed a PrPC dependent 
regulation in 9 month-old animals of Aβ1−40 but not of the toxic form Aβ1−42.  
We did not found in Prnp0/05xFAD mice the up-regulation of P-Fyn, Fyn or Cav-
1 as we found in 5xFAD mice. This suggests an important role of PrPC in 
Alzheimer’s disease as a promoter of toxic effect of Aβ oligomers. Our results 
may suggest the loss of PrPC delays the toxicity of amyloid beta. In conclusion, 
our data support a role of PrPC as a mediator of Aβ toxicity in AD by promoting 
early onset of disease.  
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I. Introduction 
 
1. Neurodegenerative Dementias 
Neurodegenerative dementias are characterized by an insidious onset that is 
followed by a gradual and slowly progressive cognitive impairment. Until now there is 
no cure for neurodegenerative dementias that result in accumulation of proteins in 
the brain which is followed by a progressive degeneration and/or death of nerve cells. 
These alterations can lead to multiple cognitive disturbances such as movement 
problems (ataxia), or mental function problems (dementia). There are many different 
forms of neurodegenerative dementia and they are histologically characterized by 
varying degrees of neuronal loss, gliosis, and usually with abnormally misfolded 
protein depositions (Josephs et al. 2009). The most common form of 
neurodegenerative dementia is Alzheimer's disease (approximately 55%), followed  
Lewy body disease (LBD), stroke/mixed dementia and frontotemporal dementia 
(Figure 1) (Waight et al. 2015). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The protein deposition nature of proteins defines the histological classification 
of each neurodegenerative dementia in three major groups: tauopathies, 
amyloidophathies and synucleinopathies, associated with the pathological 
aggregation of tau, amyloid or alpha-synuclein proteins in the brain, respectively 
Figure 1. Types of dementia: Alzheimer’s disease is the most incident. (Waight et al. 
2015) 
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(Galpern & Lang 2006). The phenotypic variability in neurodegenerative dementia 
has been investigated and a spectrum of relations between clinical syndromes and 
molecular features has been identified. Some proteins have emerged as main 
players in the mechanism of neurodegeneration. However, the molecular events 
involved in neurodegeneration remains largely unknown (Caberlotto & Nguyen 2014). 
Neurodegenerative diseases are strongly correlated with aging. European 
countries have a high ageing population, wherein about 16% of the European 
population is over 65 years-old and it is predicted to reach 25% by 2030 (JPND 
2014). The prion diseases are rare neurodegenerative diseases, and it is therefore 
difficult to know the correct prevalence of prion disease. However, studies suggest 
that about one person per million worldwide each year is affected by prion diseases 
(Anon 2015).  
 
 
1.1. Prion diseases 
Prion diseases or also called transmissible spongiform encephalopathies 
(TSEs) are a family of rare progressive neurodegenerative disorders of central 
nervous system (CNS) that affect humans and animals. Prion diseases are 
characterized by rapidly progressive neurodegeneration and mortality (Center For 
Disease Control 2012). Currently, there is no therapy available other than palliation. 
 Human prion diseases are classified into Creutzfeldt-Jakob disease (CJD),  
Gerstmann-Straussler-Scheinker Syndrome (GSS), Fatal Familial Insomnia (FFI) and 
Kuru (Table 1). In animals the prion diseases are classified into Bovine Spongiform 
Encephalopathy (BSE) in cattle, Chronic Wasting Disease (CWD) in North American 
cervids, scrapie in sheep and goats, transmissible mink encephalopathy, feline 
spongiform encephalopathy and ungulate spongiform encephalopathy (Center For 
Disease Control 2012) TSEs are distinguished by long incubation periods (years or 
even decades), multifocal spongiform changes associated with neuronal loss, 
astrogliosis and a failure to induce inflammatory response (Collinge & Alpers 2006). 
 
 
Table 1. Transmissible spongiform encephalophathies (TSEs) in humans (Liemann & Glockshuber 
1998). 
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Disease name Etiology 
Creutzfeldt-Jakob Disease: 
Iatrogenic 
Sporadic 
Inherited 
New variant 
 
Infection 
Unknown 
Mutation in PrP gene 
Infection from bovine prion? 
Gerstmann-Stränssler-Scheinker syndrome Mutation in PrP gene 
Fatal Familial Insomnia (FFI) Mutation in PrP gene 
Kuru Infection 
 
Prion diseases result from misfolding of a normal cell-surface brain protein 
called prion protein (PrPC), whose exact function is unknown. Misfolded prion 
proteins are called prions or scrapie PrP (PrPSc - It comes from the name of the 
prototypic prion disease of sheep). PrPSc are pathogenic and infectious. Prion  
disease is produces by replication where PrPSc induces conformational 
transformation of PrPC, creating PrPSc duplicates, which, in chain reactions, induces 
further transformation of PrPC into PrPSc (Figure 2). This transformation process 
spreads to various regions of the brain (Gambetti 2015). Both isoforms share 
identical amino acid sequences, but PrPSc differs biochemically from PrPC by its β-
sheet enriched structure, detergent insolubility and limited sensitivity to proteolysis by 
proteinase (Prusiner 1998). PrPSc is widely believed to be the pathogenic agent in 
prion diseases (TSEs) (Caughey et al. 1991; Pan et al. 1993). 
 
 
 
 
 
 
 
 
 
 
Figure 2. Model of PrPC isoform and PrPSc: Representation of PrPC structure, putative PrPC isoform, 
and two PrPSc models (Samson & Levitt 2011). The proposed structure of PrPC is composed by 40% 
of alpha-helix and 3% of β-sheet. When PrPC is converted to abnormal isoform, PrPSc, β-sheets 
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increased to 40% and alpha-helix decrease to 30%. Convertion of PrPC to PrPSc leads to their 
accumulation in extracellular and/or intracellular environments (Lee et al. 2013; Moore et al. 2009). 
 
 
1.1.1. Prions theory 
Over the years, researchers have suggested several theories to explain the 
causative agent of TSEs, called scrapie agent. During several years, many 
researchers postulated that TSEs were caused by “slow viruses”. However, the 
researchers were unable to isolate any virus. Subsequent studies revealed that the 
scrapie agent has many chemical properties in common with a protein molecule 
(Prusiner 1982; Prusiner et al. 1981). In 1982, Prusiner showed that the scrapie 
agent is a small proteinaceous infectious particle called the prion (Prusiner 1982). 
prion describes an abnormal folding of specific normal cellular proteins that are 
mostly found in the brain, called cellular prion proteins (PrPC) that become resistant 
to proteases and lead to their accumulation and become able to induce abnormal 
folding to others PrPC proteins (Center For Disease Control 2012) 
 
1.1.2 Human Prion diseases 
 The prion diseases in humans are very rare, account approximately 1-2 per 1 
million people in worldwide that die due to prion disease each year (Holman et al. 
2010). Prion diseases are invariably fatal and incurable becoming a significant 
concern for animal and human health. Prion diseases can occur sporadically 
(apparently starting spontaneously, without a known cause), via mutation in PRNP 
(gene of prion protein) and acquired (infectious transmission). The sporadic form of 
prion disease is the most common form of prion disease. It is estimated that 85% of 
prion disease are sporadic, 15% are genetic and <1% are acquired (Appleby & 
Lyketsos 2011; Geschwind 2015).  
To explain the occurrence of  sporadic CJD two hypotheses have been 
suggested (Prusiner 1998). The first hypotheses suggests that somatic mutation of 
prion protein gene (PRNP) is correlated with age and this mutation  could lead to 
formation of PrPres (protease resistant prion protein) (Center For Disease Control 
2012). The second hypotheses suggests that occurs by the spontaneous conversion 
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of PrPC into PrPres in a single neuron or a group of neurons, possibly after a chance 
error during prion protein gene expression (Belay 1999).  
The human prion diseases that are associated with autosomal dominant 
pathogenic mutations in PRNP (Gambetti et al. 2003; Collinge 1997; Kovács et al. 
2002; Mead 2006). It is believed that the mutation increases the tendency of PrPC to 
convert into PrPSc (Riek et al. 1998; Swietnicki et al. 1998). More than 30 autosomal 
dominant pathogenic PRNP mutations have been described (Collinge & Alpers 2006; 
Wadsworth et al. 2003; Kovács et al. 2002; Mead 2006). It has been shown that the 
homozygosity for methionine at codon 129 of PRNP gene, where either a methionine 
or a valine may be encoded, represents a risk for development of prion diseases 
(Palmer et al. 1991). 
The Inherited prion diseases are subdivided in GSS, CJD and FFI. Each sub-
division is characterized by a specific clinical syndrome, being GSS characterized by 
the presence of chronic cerebellar ataxia with later pyramidal features and dementia 
than can be seen in classical CJD (Collinge & Palmer 1997). Fatal familial insomnia 
(FFI) is characterized by progressive untreatable insomnia, thalamic degeneration, 
dementia and dysautonomia, it is most commonly associated with a missense 
mutation at codon 178 of PRNP (Medori et al. 1992). However, FFI without causative 
mutation in PRNP has been reported (Masters et al. 1985; Montagna et al. 2003).  
The iatrogenic and variant Creutzfeldt-Jakob diseases (iCJD and vCJD 
respectively) and kuru are infections forms of prion diseases associated with 
accidental transmission of PrPSc to human. Iatrogenic CJD is transmitted (Human-to-
human transmission) by cadaveric dura mater grafts, stereotactic intracerebral EEG 
needles or neurosurgical instruments, intramuscular injections of contaminated 
cadaveric pituitary-derived human growth hormone (hGH) and gonadotrophin 
hormone. Most cases of iCJD are attributed to treatment with hGH (Haïk & Brandel 
2014). Variant CJD was first described in 1996 and the earliest case had an onset of 
the illness in 1994 (Will et al. 1996). Until 2014, 229 vCJD cases have been 
diagnosed worldwide. It is believed that vCJD is due to BSE contamination of food. 
The epidemiological evidence strongly supports the view that the agent passed from 
cattle to human (Knight 1998). The phenotype of vCJD is the frequent psychiatric 
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symptoms (depression, anxiety, apathy, withdrawal and delusions) and atypical pain 
in limbs or face at clinical onset.  
Kuru is found among people from New Guinea who practiced a form of 
cannibalism in which they ate the brains of dead relatives as part of a funeral ritual. 
The clinical hallmarks of this disease are shivering (original Fore translation of 
“Kuru”) and severe cerebella ataxia accompanied with tremors (Hornabrook 1968).  
 
 
1.1.3 Conversion of PrPC into PrPSc 
Conformational change of the cellular prion protein (PrPC) to the prion protein 
scrapie (PrPSc) is considered the central event of the formation and pathogenesis of 
the infectious agent. In infection it is assumed that PrPSc comes into contact with 
PrPC, and this contact induce the conformational transition of PrPC to PrPSc (Figure 
2). Chaperone actions describe induced conformational changes of proteins, 
hereupon PrP may act as its own chaperone (Rabenau et al. 2000). In contrast to the 
α-helical-rich structure of PrPC, the tertiary structure of PrPSc shows a higher content 
of β-sheets (Riesner 2003). The misfolded PrPSc molecule seems to trigger formation 
of oligomeric structures, which then tend to form fibrils (Silveira et al. 2005; Walsh & 
Selkoe 2004). The newly generated PrPSc will be grouped in order to form new 
aggregates, or it will be integrated into already existing aggregates. These 
aggregates of PrPSc will be stabilized by aggregation thereby acquiring a much 
longer turnover time. The conformational change of PrPC to PrPSc might go on as long 
as new PrPC molecules are synthesized in the cell (Wadsworth et al. 2003; Knight et 
al. 2004).  
 
 
1.1.4 Structure and proteolytic processing of the cellular prion protein   
The cellular prion protein PrPC is a membrane glycoprotein, it is attached to 
the lipid bilayer via C-terminal, glycosyl-phosphatidylinositol (GPI) anchor 
(Westergard et al. 2007). The matured PrPC exhibits 208-220 amino-acid residues 
depending on species and the molecular mass vary between 36 to 27 KDa, 
depending on the extent of glycosylation. PrPC consists of three glycosylated forms 
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(unglycosylated, monoglycosyalted and diglycosylated) (Riesner 2003). The three-
dimensional structure of PrPC includes a disordered N-terminal domain (residues 23–
124; numbering for mouse PrP) and a C-terminal globular region (residues 125–228) 
composed of three α-helices and two short β-strands (Figure 3) (Riek et al. 1997; 
Knaus et al. 2001). The N-terminal region of PrPC encompasses a polybasic region 
(residues 23–27) and a series of histidine-containing octapeptide repeats (residues 
51–90), which can bind metal ions such as Cu2+ (Knaus et al. 2001). The residues 
encompass a charged region followed by a highly conserved hydrophobic domain 
(residues 112-130), which acts as a transmembrane anchor (Hegde et al. 1998). The 
N-terminal signal peptide (residues 1-22) is removed and GPI anchor is attached at 
residue 230, during ER biosynthesis (Stöckel et al. 1998). Two N-linked 
oligosaccharide chains are also added (at Asn-180 and Asn-196) (Stahl et al. 1987). 
The cellular proteases cleave proteolytically some amino residues of the protein 
(near residue 111) to generate N- and C-terminal fragments called N1 and C1, 
respectively (Gorodinsky & Harris 1995; Vincent et al. 2001; Biasini et al. 2012). 
 The biosynthetic pathway of PrPC is similar to other membrane and secreted 
proteins, involving synthesis on ER-attached ribosomes, transit to the Golgi, followed 
by delivery to the cell surface (Harris 1999).  
 
Figure 3. Organization of human PrP. The unprocessed PrP is 253 amino acid residues in length 
and includes a signal peptide (1–22), four OR, a hydrophobic region (113–135), one disulphide bond 
between cysteine residues (179–214), two N-linked glycosylation sites (at residues 181 and 197), and 
a GPI-anchor attached to the C-terminus of PrP replacing the GPI-anchor signal (residues 232 to 
254). The four OR in the N-terminal domain have a high affinity for copper ions (Cu2+), while a 
preceding oligopeptide (PQGGGGWGQ) lacks the histidine that is necessary to bind a Cu2+ ion. 
Mutated forms of PrP can contain insertions of one to nine additional OR or a deletion of one OR. A 
palindromic region, AGAAAAGA (113–120), lies in the hydrophobic region (113–135) and is thought to 
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be important in the conversion of PrPC to PrPSc. OR: Octapeptide repeat; GPI: 
glycophosphatidylinositol; PK: proteinase K; CHO: carbohydrates (Acevedo-Morantes & Wille 2014). 
 
 
1.1.5 Cellular prion is ubiquitously expressed  
 PrPC is expressed in all cell types although its expression is consistently higher 
in the nervous system cells (Martins et al. 2002; Martins et al. 2010; Linden, Martins, 
M. A. M. Prado, et al. 2008). The human PrPC is encoded by the PRNP gene 
chromosome at 20p13 (Prnp in mouse) and consists of two exons (Basler et al. 
1986). All known mammalian Prnp genes are encoded by a single open reading 
frame (ORF). The expression begins in early embryogenesis, and it is present at 
highest levels in neurons of the brain, in particular in synapses, and spinal cord in 
adults (Manson et al. 1992; Harris et al. 1993) and moderate levels in spleen, liver, 
heart and lung whereas kidney showed the lowest expression (Ning et al. 2005). The 
levels of prion protein is not related with PrPC mRNA levels, this suggests that PrPC is 
mainly post-translational regulated in CNS neurons (M J Ford et al. 2002). 
 
1.1.6. Physiological function of PrPC 
Many recent studies aim to elucidate the physiological function of the PrPC, 
however their function is not fully clarified. Although, a behavioral study reveals 
specific age-dependent differences between WT and Prnp0/0 mice, which indicate an 
important role for PrPC in brain function (Schmitz et al. 2014). Overexpression of 
PrPC seems to be protective in cell lines and primary neurons from several kinds of 
apoptotic stimuli (Shyu et al. 2005; Milhavet & Lehmann 2002; Kim et al. 2004; 
Roucou et al. 2003; Diarra-Mehrpour 2004). Beyond that, PrPC has been shown to 
play a role in regulating intracellular signaling cascades, including those mediating 
cellular survival (Lo et al. 2007). For example, in Knockout PrPC (Prnp-null) animals 
circadian rhythm was altered (Tobler et al. 1996), and abnormal synaptic structure in 
the hippocampal formation was observed (Brown 2001). Several functions have been 
proposed for PrPC including a role in oxidative stress (Das et al. 2010), immune 
modulation (Panigaj et al. 2011), differentiation (M. J. Ford et al. 2002), translocation 
of metals, such as copper (Pauly & Harris 1998), alteration of copper, zinc and iron 
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homeostasis in the brain (Pushie et al. 2011), cell adhesion; and transmembrane 
signaling (Linden, Martins, M. a M. Prado, et al. 2008). Most studies indicate that 
PrPC may be associated with multi-molecular membrane complexes, which mediate 
several functions in distinct cellular compartments (Kim et al. 2004). The availability 
of PrPC at the cell surface depends on its cycle between plasma membrane and 
endocytic compartments. This process is also involved in pathways of internalization 
that may be critical for PrPC physiological functions (Negro et al. 2001). Several 
studies have indicated a direct high affinity interaction between Aβ (neurotoxic 
peptide in AD) and PrPC. Indeed, there is evidence that PrPC may play a critical role 
in the pathogenesis of Alzheimer’s disease (Kellett & Hooper 2009). 
 
1.2 Alzheimer’s disease 
Alzheimer’s disease (AD) is the most prevalent age-related neurodegenerative 
disease (around 60% of dementia cases) that leads to cognitive impairment and 
dementia (Rial et al. 2012). The principal risk factor for AD is age, but it is not a 
normal part of aging. Approximately 5-10% of population exhibiting an age of 65 
years have AD and the prevalence of this disease increases with increasing age from 
19% to 30% after 75 years of age (Figure 4) (Iris Medical Education 2015). 
 
 
 
 
 
  
 It has been identified two distinct forms of AD, the familial Alzheimer's disease 
(FAD) and the sporadic Alzheimer's disease (SAD) (Ling et al. 2003; Bertram et al. 
2010). About 90-95% of Alzheimer`s disease represents a sporadic form and 5-10% 
represents familial form. AD is an irreversible, progressive neurodegenerative 
Figure 4. Percentage of people with Alzheimer’s disease worldwide (Iris Medical Education 2015). 
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disorder (Khachaturian & Radebough 1996). It leads to the progressive loss of 
mental, behavioral, functional decline and ability to learn (Anand et al. 2014). The 
definitive diagnosis is established post mortem through the histopathological 
analyses of patient’s brain and there is none available effective treatment or 
preventive therapy (Eva Babusikova 2011). Neurochemical and pathological 
characteristic changes of AD are tissue atrophy caused by loss of synapses which is 
most striking in frontal and temporal areas of the brain cortex, gliosis and formation of 
two main protein clusters in extracellular and intracellular region of the brain (Eva 
Babusikova 2011). Extracellular deposits (amyloid plaques) occur most frequently in 
neocortex. They consist of 4kDa, 40-42 amino acid polypeptide chain called amyloid 
β peptide (Aβ) (Glenner & Wong 1984). The intracellular deposits are generated from 
filaments of microtubular hyperphosphorylated tau protein leading to the neurofibrilar 
tangles (Alonso et al. 2008; Grundke-Iqbal et al. 1986; Lee et al. 1991). In AD the 
dysregulation of intracellular calcium plays an important role in the pathogenesis. It is 
thought that neurodegeneration induced by Aβ and hyperphosphorylated tau may be 
mediated by changes in calcium homeostasis. Persistent changes in calcium 
homeostasis are proximal reasons of neurodegeneration in AD patients 
(Khachaturian 1989). Tau is a neuronal microtubular associated protein and it is 
assumed that it plays a major role in the conservation of cells shape and in axonal 
transportation (Buée et al. 2000). Amyloid plaques and neurofibrilar tangles are 
characteristic of AD, and they are present in different neurodegenerative pathological 
situations (Robert & Mathuranath 2007). The aggregates are involved in a process 
which leads to progressive degeneration and to neuronal death. Two main 
hypotheses explaining the cause of AD development were proposed: (1) hypothesis 
of amyloid cascade – a neurodegenerative process is a serial of events started by an 
abnormal processing of amyloid precursor protein (APP) [Hardy and Higgins, 1992], 
and (2) hypothesis of neuronal cytoskeletal degeneration (Braak & Braak 1991). 
According to the amyloid hypothesis accumulation of amyloid beta (Aβ) plaques acts 
as a pathological trigger for a cascade that includes neuritic injury, formation of 
neurofibrillary tangles via tau protein hyperphosphorylation, leading to neuronal 
dysfunction and cell death in AD (Hardy & Higgins 1992; Selkoe 1999; Dickson 
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1997). The cellular mechanisms of Aβ oligomer/plaque formation neurotoxicity are, 
however, controversial (Rushworth et al. 2013).  
 
1.2.1 Familial Alzheimer's disease (FAD) 
In humans, FAD is caused by autosomal dominant mutations in three genes. 
Gene for amyloid precursor protein (APP) 21q21.3 (Goate et al. 1991), presenilin 1 
(PSEN1) on chromosome 14q24.2 and presenilin 2 (PSEN2) on chromosome 
1q42.13 (Campion et al. 1995; Cruts et al. 1995; Sherrington et al. 1996). These 
mutations are responsible for a high production of Aβ that may accumulate and form 
amyloid plaques. The gamma-secretase complex include presenilins and wich are 
involved in amyloid processing of APP. PSEN1 and PSEN2 mutations are linked to 
early onset of AD. Mutations of presenilin 1 may cause the cleavage alterations of 
APP and production of Aβ1-42, the most pathological variant for generation of amyloid 
plaques in the brain (Xia et al. 1997; Eva Babusikova 2011). Aβ level increase years 
before any clinical symptoms of Alzheimer’s disease are observed. Interestingly, 
mutations in the tau gene are not associated with AD. 
 
1.2.2 Sporadic form of Alzheimer's disease 
The sporadic for of AD is thought to be a multifactorial combination of aging, 
genetic predisposition, and exposure to environmental agents including low 
education, head trauma, toxins and viruses. However, no environment agents have 
been proven to be directly involved in pathogenesis of AD (Bird 2015). Apolipoprotein 
(apo) E4 has been genetically linked to late-onset of AD. An individually carrying a 
mutation on APOE4 allele have 3 to 15 times increased risk of developing AD. Risk 
genes increase the likelihood of developing a disease, but do not guarantee it will 
happen (Duthey 2013). 
 
1.2.3 Physiological function and processing of Amyloid precursor protein 
The amyloid precursor protein (APP) is a type I transmembrane glycoprotein 
that is expressed in a wide variety of mammalian cells (Müller-Hill & Beyreuther 
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1989). The physiological function of APP and its homologues remains unclear, but its 
role has been suggested in neural protein trafficking along the axon, cell adhesion, 
neurite outgrowth and synaptogenesis and calcium metabolism (Zheng & Koo 2006). 
 In humans, of the 19 exons which encode  APP, exons 7, 8, and 15 are 
subject to alternative splicing (Ling et al. 2003). APP variants result from differential 
splicing of APP during transcription. The common expressed isoforms of APP have 
770, 751 and 695 amino acid residues. APP695 is the predominant neuronal isoform 
(Kang et al. 1987). 
The mRNA splice variants of APP are expressed in different cells in different 
amounts. Since APP has a widespread expression and distribution it has been 
suggested to play an important role (Dawkins & Small 2014). APP can be post-
translationally processed by enzymes termed α-, β-, and γ-secretases, which can 
cleave the protein to produce and release a number of smaller amyloid fragments 
(Selkoe 2001; De Strooper & Annaert 2000). On the cell surface, the APP can be 
cleaved by α-secretase (non-amyloidogenic pathway) or β-secretase (amyloidogenic 
pathway) (Figure 5). The non-amyloidogenic processing of APP occurs via the α-
secretase pathway, which cleaves on the C-terminal side of residue 16 of the Aβ 
sequence, generating a 83-residue C-terminal fragment (C83) and releases a large 
soluble ectodomain of APP called sAPPα (Esch et al. 1990). Subsequent cleavage 
by γ-secretase releases a short peptide (p3) and generates the APP intracellular 
domain (AICD). In the amyloidogenic pathway the β-secretase cleaves APP between 
Lys16 and Leu17 or Tyr10 and Glu11 to produce sAPP-β that is released to the 
extracellular medium, the fragment that stayed embedded in the membrane is called 
C99. This fragment (C99) is subsequently cleaved by y-secretase in a cleavage to 
produce Aβ peptide and the smaller AICD (Pitsi & Octave 2004; Maltese et al. 2001; 
Motoki et al. 2012; Vetrivel et al. 2009). The majority of Aβ have 40 amino acids 
residues in length (Aβ1-40), however the γ-secretase cut is imprecise and creates Aβ 
isoforms of different lengths, between 39 and 43 amino acids residues in length. The 
length of Aβ peptide varies at C-terminal according to the cleavage pattern of APP. 
The Aβ1–40 isoform is the most prevalent, followed by Aβ1–42 which is hydrophobic 
in nature and aggregates at a faster rate than Aβ1–40 (Walsh & Selkoe 2007; Perl 
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2010). Aβ1–42  is the major protein component of amyloid plaques in the Alzheimer's 
disease brain (Masters et al. 1985). 
 
1.2.4 β-amyloid peptide (Aβ)  
 In AD, amyloid fibrils are formed from Aβ peptide (Finder & Glockshuber 
2007). This peptide is produced at cholesterol-rich regions of neuronal membranes 
and secreted into the extracellular space (Simons et al. 1998). The cleavage of APP, 
in amyloidogenic pathway, results in a number of Aβ isoforms, Aβ1-40 and Aβ1-42 
are the most commonly found. These two forms are capable to adopt many 
differently shaped aggregates including amyloid fibrils (Meinhardt et al. 2009; Lührs 
et al. 2005; Kodali & Wetzel 2007; Sachse et al. 2008) as well as nonfibrillar 
aggregates that are sometimes also termed Aβ “oligomers” (Haass & Selkoe 2007; 
Glabe 2008). The more amyloidogenic isoform is Aβ1-42. It aggregates more readily 
and it is predominantly found in senile plaques. Despite Aβ peptide and Aβ amyloid 
plaques are commonly outside the cell  (Pepys 2006; Meyer-Luehmann et al. 2003), 
considerable evidences points towards a potential relevance of intracellular Aβ 
(Takahashi et al. 2002; Rajendran et al. 2007; Oakley et al. 2006; Du et al. 2008). 
Monomeric Aβ is generally non-toxic, although there is evidence that Aβ oligomers 
are responsible for the synaptic dysfunction that occurs in AD (Walsh et al. 2002; 
Cleary et al. 2005). Aβ oligomers are toxic for cells (Yankner et al. 1989) by different 
pathways and their toxicity correlates with the level of aggregation. The peptide is 
capable to influence metabolic pathways in the brain. It is able to activate effectors of 
apoptosis, caspases, to affect calcium homeostasis by increasing the amount of 
intracellular calcium concentration (Mattson et al. 1993; Eva Babusikova 2011), and 
to induce neuronal death. 
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Figure 5. Formation of amyloid (A) and neurofibrillary tangles (B) in the neurons in Alzheimer’s 
disease (Fonseca-Santos et al. 2015). 
 
 
2. Prion protein and Alzheimer’s disease 
There are several pathological similarities and genetic connections among AD 
and prion diseases.  The coexistence of AD in CJD has been described (Hainfellner 
et al. 1998), and PrPC has been shown to co-localize with Aβ plaques (Voigtländer et 
al. 2001). The PrPC- Aβ  plaques were present in most of CJD patients with AD-type 
pathology (Del Bo, et al., 2006) and it has been postulated that PrPC may promote 
Aβ plaque formation, also a genetic correlation among PrPC and AD has been 
reported. However, there was no evidence of an interaction between both proteins 
involved in these diseases despite pathological and genetic links between them 
(Schwarze-Eicker et al., 2005). 
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3. Aims of the present study 
The main task of the present study is to investigate the role of the cellular 
prion protein (PrPC) in AD, which is still unclear because previous studies showed 
contradictious results (Parkin et al. 2007; Laurén et al. 2009). While Parkin et al. 
(2007) observed an inhibitory function of PrPC on the processing of APP resulting in a 
reduced amount of Aβ, Laurén et al. (2009) reported an interaction of PrPC and Aβ 
which enhances the toxicity of Aβ. By this, PrP potentially acts as receptor for 
amyloid beta mediating the toxicity of amyloid beta-oligomers in an AD mice model 
(Laurén et al. 2009; Gimbel et al. 2010). To elucidate this issue, the main objective of 
the present study is to investigate the influence of a knockout of the Prnp gene in 
5XFAD mice, exhibiting 5 mutations related to familial Alzheimer disease. These 
mice express the 695 aminoacids isoform of the human amyloid precursor protein 
(APP695) carrying the Swedish/London/Florida mutations under the control of the 
murine Thy-1-promoter. In addition, human presenilin-1 carrying the M146L/L286V 
mutations is expressed also under the control of the murine Thy-1-promoter. These 
mice are commercially available and show an Aβ1-42 accumulation and an increased 
neuronal loss during aging (Eimer & Vassar 2013). To create a bi-transgenic mice 
line 5xFAD mice were crossed with Prnp0/0 Zurich 1 mice (Büeler et al. 1992). 
In the present study, the role of PrPC in AD shall be defined  by subjecting two 
transgenic mice (5xFAD and Prnp0/05xFAD) at different ages (3, 9, 121 months of 
age) to a battery of behavioral task, including the open field, elevated plus maze, 
novel object recognition rotarod task. With these tests, potential deficits in mice 
behavior (locomotor activity, learning and memory performance, motor function or 
anxiety behavior) will be analyzed in 5xFAD and Prnp0/05xFAD mice in comparison to 
a corresponding control group consisting of PrPC wild type (WT) and PrPC knockout 
mice (Prnp0/0). In addition, comprehensive biochemical analysis, which include 
western blotting, ELISA, immunohistochemical staining should be undertaken to 
quantify the amount of Aβ1-40 and Aβ1-42 in mice during aging, to analyze the amount 
and distribution of Aβ deposits dependent of PrP, and to investigate the regulation 
and potential involvement of downstream signaling proteins in the Aβ induced toxicity 
dependent of the PrP concentration. 
 
 
                                                          
1 12 months of age group is only composed by Prnp0/0 and Prnp0/0 5xFAD due to the low availability of 5xFAD. 5xFAD mice have 
a high mortality after 9 months of age. 
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II. Materials 
 
1. Chemicals 
All chemicals used in this study were obtained from Applichem (Darmstadt, 
Germany), Biochrom AG (Berlin, Germany), Bio-Rad (München, Germany) Merck 
(Darmstadt, Germany) Roth (Karlsruhe, Germany) and Sigma-Aldrich (Steinheim, 
Germany) if not stated otherwise in the text.  
Reaction tubes, pipette tips and laboratory glassware were autoclaved or sterile 
prior to use. 
 
 
1.1 Antibodies  
Antibodies used for immunoblotting (IB) and immunohistochemistry (IHC) are 
listed in Table 2. 
 
Table 2. List of antibodies and respective dilutions were used for Western blot analysis after SDS-
PAGE. 
Antibody Dilution Supplier 
APP 1:1000 Abcam, Cambridge, UK 
Anti-β-actin-antibody 1:1000 Abcam, Cambridge, UK 
Anti-Fyn 1:1000 Abcam, Cambridge, UK 
Anti-P-Fyn 1:1000 Abcam, Cambridge, UK 
Anti-Caveolin 1 1:1000 Abcam, Cambridge, UK 
Anti-GAPDH 1:1000 Abcam, Cambridge, UK 
Anti-SAF-32 1:1000 Abcam, Cambridge, UK 
Anti-beta Amyloid 1:500 Abcam, Cambridge, UK 
AP-conjugated anti-
mouse IgG 
1:2000 Santa Cruz Biotechnology, Santa Cruz, USA 
AP-conjugated anti-
rabbit IgG 
1:2000 Santa Cruz Biotechnology, Santa Cruz, USA 
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1.2. Kits  
All the listed kits were used according to the manufacturer’s instructions.  
 
Table 3. List of the kits used in this study 
Name Company 
DNeasy Blood & Tissue kit Qiagen, Hilden, Germany 
Elisa essay Aβ1-40 IBL, International 
Elisa essay Aβ1-42 IBL, International 
 
 
1.3. Oligonucleotids 
All mice were genotyped by PCR amplification for 5xFAD and Prnp0/0 mutation 
and Prnp+/+. 
 
Table 4. List of Oligonucleotids 
Primer Sequence in 5’ – 3’ orientation Supplier 
Mu_PrP_WT_for 
(Prnp+/+allele) 
ATGGCGAACCTTGGCTACTGGGCTG Operon 
 
Mu_PrP_WT_Rev 
(Prnp+/+allele) 
CATCCCACGATCAGGAAGATG Operon 
 
oIMR3611_For 
5xFAD 
CGGGGGTCTAGTTCTGCA Operon 
 
oIMR3610_Rev 
5xFAD 
AGGACTGACCACTCGACCAG Operon 
 
P3 (Prnp0/0 allele) ATTCGCAGCGCATCGCCTTCTATCGCC Operon 
 
P4 (Prnp0/0 allele) CATCCCACGATCAGGAAGATG Operon 
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1.4. DNA and Protein Standards 
All the listed DNA and Proteins Standards were used according to the manufacturer’s instructions. 
 
Table 5. List of DNA and Protein Standards 
DNA and Protein Standards Supplier 
100bp Standard DNA marker New England Biolabs,  Frankfurt am  Main, 
Germany 
Precision Plus Protein Standards (dual color) Bio-Rad, München, Germany 
 
 
2. Buffers and Solutions 
 
Blocking solution for WB: 5% milk powder in TBST 
Electrophoresis buffer (SDS-running buffer): 192mM Glycine, 0.1 SDS, 25mM Tris-
HCL pH 8.3. 
ECL (A): 2.5mM Luminol, 0.4mM p-Coumar acid, 0.1M Tris-HCL pH 8.5 
ECL (B): 18% H2O2, 0.1M Tris pH 8.5 
Lysis buffer (tissue): 50mM Tris pH 8.0, 150mM NaCl, 1% Triton-X-100 
TBST (10x): 200 mM Tris, 1.5M NaCl, 1% Tween-20  
Transfer Buffer for WB: 192mM Glycine, 20% Methanol, 25mM Tris-HCl pH 8.3 
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3. Instruments and other materials  
 
Table 6- List of the instruments used in this study 
Appliance Model or Description 
 
Manufacture 
 
Bio-safety Cabinet Hera safe KS 
 
Heraeus/ Osterode, Germany 
 
Centrifuge 
 
5415C 
 
Eppendorf/Hamburg,Germany 
 
Centrifuge Rotina 35R 
 
Hettich/ Tuttlingen, Germany 
 
Chamber slide 
 
Lab-Tek™ II Chamber Slide, 
15453 
nunc/ New York, USA 
 
Electro blotting apparatus 
 
Mini Trans-Blot® 
 
Bio-Rad /Munich, Germany 
 
Electrophoresis apparatus 
 
Mini-Protean® III 
 
Bio-Rad /Munich, Germany 
 
Heated magnetic stirrer 
 
iKAMAG RCT 
 
IKA-Labortechnik/Staufen, Germany 
 
Ice machine 
 
- Ziegra /Isernhagen, Germany 
 
Microscope 
 
Zeiss LSM 510 Meta 
 
Carl Zeiss/ Goettingen, 
Germany 
Power supply Power Pac 300 
 
Bio-Rad /Munich, Germany 
 
Safe-Lock tubes  
 
0.2, 0.5, 1.5 and 2ml 
 
Eppendorf /Hamburg, Germany 
 
Serological pipettes 2, 5, 10, 25ml 
 
Sarstedt /Germany 
 
plastic tubes 15 and 50ml Sarstedt /Germany 
 
pH meter pH 526 
 
WTW/ Weilheim, Germany 
Shakers CERTOMAT R 
 
Sartorius/ Goettingen, 
Germany 
Spectrophotometers EL808 
 
Bioteck instruments/Winooski-vermont, 
USA 
Sterile filter Nalgene 0.2μm Sartorius/ Goettingen, Germany 
Sterile filter pipette tips 
 
-  Biozym /Oldendorf, Germany 
Thermomixer 5436 
 
Eppendorf/ Hamburg, 
German 
Vortexer Genie 2™ 
 
Bender and Hobein /Zurich, Switzerland 
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4. Software  
The following is a list of scientific software used in the study.  
 
Table 7- List of scientific software 
Program 
 
Use 
 
References 
 Graphpad Prism 5 
 
Statistical analysis 
 
GraphPad Software, Inc. California, USA 
ImageJ 1.43u 
 
Densitomatric analysis 
 
National institutes of Health, USA 
KC4 V3.4 
 
Absorbance reader 
 
Bioteck instruments, USA 
LabImage 2.7.1 
 
Densitomatric analysis 
 
Kapelan GmbH, Halle, Germany 
Zeiss LSM 4.2.0.121 
 
Immunofluorescence 
 
MicroImaging GmbH, Goettingen, Germany 
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III. Methods 
 
1. Molecular experiments 
1.1. Extraction of genomic DNA 
 The DNA was purified from tail biopsies with DNeasy Blood & Tissue kit 
(Qiagen). The piece of the tail (0.4cm) was placed in a microcentrifuge tube. It was 
added 180 μl Buffer ATL and 20μl proteinase K. After addition the sample was briefly 
mixed by vortexing and incubated at 56ºC overnight. The samples were mixed by 
vortexing after lysis. Following addition of AL solution and 100% ethanol and mixed. 
The mixture (including any precipitate) was pipetted DNeasy Mini spin column placed 
in a 2 ml collection tube and centrifuged at 8000 rpm for 1 min. The mini spin column 
was placed in a new collection tube and 500 µl Buffer AW1 was added and 
centrifuged for 1 min again. The mini spin column was replaced for a new one and 
added 500 µl Buffer AW2, and centrifuged for 3 min at 14,000 rpm to dry the DNeasy 
membrane. The DNeasy Mini spin column was placed in a clean 2 ml microcentrifuge 
tube, and pipetted 200 µl Buffer AE directly onto the DNeasy membrane. It was 
Incubated at room temperature for 1 min, and then centrifuged for 1 min at 8000 rpm 
to elute. The last step was repeated twice.  
 
 
1.2. Polymerase chain reaction   
 The choice of the target DNA is, of course, dictated by the specific experiment. 
However, one thing is common to all substrate DNAs and that is they must be as 
clean as possible and uncontaminated with other DNAs. When setting up multiple 
PCR experiments, it is better to assemble a mixture common to all reactions (master 
mix). Master mix was added to DNA. The experiment was performed in ice. Afterward 
all tubes were gently mixed and centrifuged to collect all liquid to the bottom of the 
tube. All mice were genotyped by PCR for 5xFAD and Prnp0/0 mutation. 
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Table 8 – PCR Solutions 
Component 25 μl reaction Final Concentration 
10X Standard Taq Reaction Buffer 2.5 μl 1X 
10 mM dNTPs 0.5 µl 200 µM 
10 µM Forward Primer 0.5 µl 0.2 µM (0.05–1 µM) 
10 µM Reverse Primer 0.5 µl 0.2 µM (0.05–1 µM) 
Template DNA 1 µl <1,000 ng 
Taq DNA Polymerase 0.125 µl 1.25 units/50 µl PCR 
Nuclease-free water to 25 µl to 50 µl 
 
 
1.2.1. Thermocycling conditions for PCR 
For the PCR reaction the following programs were used: 
 
Table 9 – PCR programs 
Mutation 5xFAD Prnp +/+ 
 
Prnp 0/0 
 
STEP  TEMP TIME  TEMP TIME  TEM
P 
TIME  
Initial 
Denaturation  
95°C  3 min 95°C  3 min 95°C
  
1 min 
30 C 95°C 
56°C 
72°C 
30 seconds 
60 seconds 
1 minute 
95°C 
56°C 
72°C 
30 seconds 
45 seconds 
1 minute 
and 15 
seconds 
95°C 
62°C 
72°C 
30 seconds 
2 minutes 
1 minute  
Final Extension 72°C 6 minutes 72°C 10 minutes 72°C 5 minutes 
Hold 4°C   4°C   4°C   
 
 
1.3. Preparation of mice’s brain samples 
The mice were sacrificed after behavioral experiment by euthanizing via CO2 
asphyxiation and then cervically dislocated.  Dissection was carried out of neuronal 
tissue and brains separated bilaterally into two equal parts. The cortex that covers 
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the hippocampus was removed and used as sample for molecular experiments.  The 
brains’ parts and the cortex were stored at -80 oC. 
 
 
1.4. Tissue Lysate  
Immediately after mice sacrifice, brain tissues were frozen in dry ice and 
stored at -80 °C. The homogenization consists in placing a metallic bead in the 
eppendorf with frozen cortex sample and homogenize with ultra sonicator on ice. The 
tissue was lysed in lysis buffer (NaCl, Tris HCl, EDTA and Tx) containing protease 
and phosphatase inhibitor cocktail (Roche), for 30 min. Lysed tissue was centrifuged 
at 13000 rpm for 15 mins at 4 °C and supernatant was obtained for further protocols. 
 
 
1.5. Bradford assay 
The protein concentration was determined by the Bradford assay (Bio-Rad). 
Working solution was prepared by diluting a dye reagent concentrate (Bio-Rad) with 
dH20 in ratio 1:5 followed by filtration through whatmann filter paper. The protein 
standards were prepared in a concentration range between 0.05-1 mg/ml. Protein 
samples of unknown concentration were diluted 1:20 in dH2O. 980 µl of Bradford 
solution was added and samples were incubated for 10 min at RT. The absorbance 
of the samples was measured at 595 nm.  
 
 
1.6. SDS-PAGE and Western blot 
Western blotting uses specific antibodies to identify proteins that have been 
separated based on size by gel electrophoresis. The immunoassay uses a 
membrane made of nitrocellulose or PVDF (polyvinylidene fluoride). The gel is 
placed next to the membrane and application of an electrical current induces the 
proteins to migrate from the gel to the membrane. The membrane can then be further 
processed with antibodies specific for the target of interest, and visualized using 
secondary antibodies and detection reagents.  
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30 µg of normalized protein samples for protein content were adjusted to an 
equal final volume and mixed with 4x SDS loading buffer (Roti®-Load). After boiling 
at 95° C for 5 min samples were loaded into the SDS-polyacrylamide gel, 10–17 %. 
Proteins were separated in the gel, running at 100 V for approximately 2h and then 
transferred to a PVDF membrane (Amersham Bioscience) by blotting. After protein 
transfer the membrane was blocked at RT for 1h. The blocking solution was set in 
accordance with specific antibody requirements. First antibody was incubated at 4° C 
overnight. Subsequently the membrane was washed with TBST at RT 3 times for 5 
min. Then the second antibody was applied at RT for 1h. Finally, after the final 
washing, the enzymatic reaction was performed using ECL solution and visualized 
with Molecular Imager ChemiDoc XRS+ with Image Lab Software (Bio-Rad). 
Densitometric values for each band intensity were determined using lab image 2.7.1 
data analyzer software. 
 
1.7. Enzyme Linked Immuno-Sorbent Assay (ELISA) 
For ELISA analysis all procedures were performed according to supplier’s 
recommendations. Briefly, equal amounts of protein from tissue lysates were added 
to a microtitre plate coated with a monoclonal antibody. The antigen binds to the 
immobilized (captured) antibody. After washing, a monoclonal antibody specific for 
the protein is added to the wells. Bound antibody is detected by the use of a 
secondary peroxidase-labeled antibody. After removal of excess of antibody, a 
substrate solution is added, which is activated by the bound enzyme to produce 
color. The intensity of this colored product is directly proportional to the concentration 
of protein present in the original sample 
 
1.8. Immunohistochemistry 
Tissue slices from liver were made with cryosect, fixed with acetone. 
Immunohistochemistry was performed with following steps; The slides were blocked 
10 minutes in 0.3% H2O2 solution in PBS at room temperature to endogenous 
peroxidase activity. After washing 3 times (PBS) the slides were blocked wit 10% 
fetal bovine serum in PBS. It was applied 6E10 antibody diluted in 1:500 an 
appropriately diluted primary antibody to the sections on the slides and incubated in a 
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humidified chamber for 90 min at room temperature. After 3 times washing with PBS, 
tissue slices were incubated with an appropriately diluted (1:200) biotinylated 
secondary antibody at room temperature 60 minutes. Incubation with secondary 
antibodies was followed by 3X washings with PBS. Extravidin (1:000) was placed for 
30 minutes on slides. After washing step the slides were incubated with AEC solution 
(3-Amino-9-Ethylcarbazole) for 30 minutes and then washed with ddH2O. The slides 
were immersed in hematoxylin for 13 seconds and rinsed in running tap water for 10 
minutes. The slides were mounted with mounting medium (fluoromount) and covered 
with coverslips followed by microscopic examination.  
 
 
2. Behavior experiments 
 
2.1. Experimental Animals 
Experiments were carried out with four different transgenic mice, wild type 
mice, 5xFAD mice (over expressed the K670N/M671L (Swedish), I716V (Florida), 
and V717I (London) mutations in human APP (695) and M146L and L286V mutations 
in PS1), PrP knockout (Prnp0/0) mice (described by Bueler et al., 1992) and (bi)-
transgenic mice line exhibiting Prnp0/05xFAD. 
 
 
2.2. General procedures  
The mice were housed one per cage in a temperature-controlled room 
(23士2°C) with 12-h light/dark cycle. All behavioral testing were performed during the 
light portion of the cycle. Mice were 3–14 months old and they had free access to 
food and water in their home cages. 
Experimental mice were carried to the test room in their individual cages, 30 
min prior to test beginning for adaptation to the condition of the behavior testing 
room.  
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2.3. Nest Building  
Behaviors associated with nest building are highly linked to survival capacity of 
wild mice. The nest provides a shelter from predators, hiding-place or camouflaging 
the mouse. The small size of mice make them vulnerable to heat loss and the nest 
protect them against harsh environments. Male and female mice build a nest when 
they are provided with a suitable building material. They are highly motivated to build 
a nest even in captivity. The changes in the highly motivated behaviors, or the nest 
itself, indicate a significant alteration in the environment or of animals behaviour, for 
instance, pain, illness, or other stressors that may affect or reduce animal's overall 
welfare (Gaskill et al. 2013). 
On the first day of testing, one piece of a tissue paper (36 cm x 12 cm) was 
placed in the cage to facilitate nest building. The presence and the quality of the nest 
were evaluated on the following day on a modified five-point scale according to the 
method of Deacon (Deacon 2006). 
A) Tissue not noticeably touched (>90% intact, 1 point)   
B) Tissue partially shredded (50-90% remained intact, 2 points) 
C) Mostly shredded but not identifiable as a nest (>50% of the tissue is 
shredded, 3 points). 
D) A nearly intact nest can be identified, with flat walls (>90% of the tissue 
is shredded, 4 points) 
E) An intact nest, with a crater whose walls are higher than mouse body 
height (100% of the tissue is shredded, 5 points). 
 
2.4. The open field  
The open field (OF) test provides an opportunity to systematically assess 
novel environment exploration, provides an initial screen for anxiety behavior and 
measure general locomotor activity levels into the arena in rodents (Bailey & Crawley 
2009). The test is based on conflicting innate tendencies to avoid the bright light and 
open spaces (that ethologically mimic a situation of predator risk) and of exploring 
novel environment. (Open-field test for anxiety) The number of line crosses and the 
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frequency of rearing are usually used as measures of locomotor activity, exploration 
and anxiety. The number of central square entries and the duration of time spent in 
the central square are measures of exploratory behavior and anxiety (MPD - Brown1 
- protocol). 
The experimental animals were placed in a dimly observation cage 
(72x72cm). The maze was divided virtually in sixteen 18x18cm squares (squares 
number six, seven, ten and eleven correspond to the imaginary central zone and the 
remaining twelve squares correspond to peripheral zone). The activity of the mice 
was monitored by a video motility system (Video-Mot II, TSE, Bad Homburg, 
Germany). Locomotor activity (squares crossed) and anxiety (locomotion in center 
squares) was measured. The open field was used in a single testing session. The 
mice were placed in one of the four corners of the open field and were allowed to 
explore the apparatus for 5 minutes. After the test, the apparatus was cleaned with 
70% ethanol and allowed to dry between tests.  
 
 
2.5. Novel Object Recognition 
Novel object recognition is a test of learning and memory. The NOR test 
becomes commonly used for investigation of memory alterations.  The mice were 
exposed to specific objects in a single trial. During the test trial, one familiar object 
was removed and replaced by a novel object. The preference for a novel object 
means that the familiar object exists in animals’ memory (Ennaceur 2010).  The total 
time spent exploring both objects during the test and training phase and 
discrimination index, i.e., the difference between the time spent exploring novel 
object and familiar object, during test phase can be considered (Antunes & Biala 
2012). 
The experimental apparatus consisted of a white rectangular open field 
(72x72cm). For performing the test we used two identical objects and other different 
from these two. The objects were a plastic rectangular box and a lego piece. The 
activity of the mice was monitored by a video motility system (Video-Mot II, TSE, Bad 
Homburg, Germany). A 3-day procedure was used. Habituation took place by 
exposing the animal to the experimental apparatus for 5 min in the absence of 
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objects one time. Twenty four hours after the habituation, two identical objects were 
placed in the open field. The mice were placed in an opposite corner to the objects 
into open field maze and they were allowed to explore for 5 minutes. After a retention 
interval of 24h, mice were placed again in the apparatus with the same two identical 
objects for 5min. Post-familiarization session the animals were transferred to their 
home cages for 5min interval. Following this period, the animal was re-introduced 
into the arena for the test session. Now, a triplicate of the familiar and a novel object 
were placed in the arena and the animal was allowed to explore during a 5 minutes 
test session. The open field and the objects were cleaned with 70% ethanol to 
minimize the olfactory cues between mice. 
The percentage of time spent exploring the novel object (TN) relative to the 
total time spent exploring both objects (TN+TF) was used to calculate the index of 
recognition memory [RI = TN/(TN + TF)]. 
 
 
2.6.  Elevated Plus Maze 
The elevated plus maze is a simple method for assessing anxiety responses 
of rodents (described (Pellow et al. 1985). It is given the choice to the mice of 
spending time in open, unprotected maze arms or enclosed, protected arms, all 
elevated approximately 50cm from the floor. The test relies upon rodents’ proclivity 
toward dark, enclosed spaces (approach) and an unconditional fear of heights/open 
spaces (avoidance) (Brain 1976). This approach–avoidance conflict results in 
behaviors that have been correlated with increases in physiological stress indicators 
(Holmes et al. 2003). The relevant behaviors are the time spent and entries made on 
the open and closed arms. 
 The apparatus used for the elevated plus maze test comprises two open arms 
60cm across from each other and perpendicular to two closed arms 60cm with a 
center platform 10cmx10cm. The closed arms have a high wall 20cm to enclose the 
arms, whereas the open arms have no walls. The entire apparatus is 50cm above the 
floor and is placed in an empty square (70x70cm) to protect the fallen mice to escape 
during the experiment. 
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The mice were placed in the center of the platform and they were allowed to 
explore the apparatus for 5 minutes, during this time a video tracking system 
recorded their behavior (Video-Mot II, TSE, Bad Hamburg, Germany). After the test, 
the apparatus was cleaned with 70% ethanol and allowed to dry between sessions. 
The time spent in the open arms, closed arms and central zone was analyzed.  
 
 
2.7. Rotarod  
Before aspects of behavior such as emotionality or cognition it is vital to 
determine motor capabilities of mice. The rotarod is designed to test balance and 
motor coordination in which the animal is placed on a horizontal rod that rotates 
about its long axis. The animal must walk forward to remain upright and not fall off 
(Deacon 2013). This test requires motor skills, including coordination of the body.  It 
is measured the time (latency) it takes the mouse to fall off the rod rotating at 
different speeds or under continuous acceleration (e.g. from 4.0 to 40rpm). 
To measure motor coordination mice were placed on a computerized treadmill 
(TSE rotarod system). Mice were trained for 5 consecutive days at constant speed 
(5.0 rpm) for a maximum duration of 280 sec. per trial. The testing day consisted of 2 
trials with 5min intertrial intervals, mice were placed on an accelerating rotarod from 
4.0 – 40rpm for 280 sec and the latency to fall was measured. Rotarod performance 
was assessed by evaluating the best trial out of two performed in the test day. 
 
 
2.8. Fear Conditioning  
Fear conditioning is a test of memory and learning in which mouse learn to 
associate a context and cue with an unconditioned stimulus. During training phase, 
the mouse was exposed to a chamber in which the cue (white noise) is paired the 
stimulus (footshock). When the animal is returned to the same environment without 
the footshock and cue, it generally will demonstrate a freezing response if it 
remembers and associates that environment with the aversive stimulus. On a second 
trial it is presented to the mouse an altered context and is introduced the white noise 
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cue, once again, if the mouse remembers the aversive stimulus it will display a 
freezing behavior, which is the normal response of fearful situations. Freezing 
behavior is defined as complete immobility with the exception of breathing. The 
freezing episodes and time are recorded for evaluation (Shoji et al. 2014). 
The apparatus for the fear conditioning and context test is an acrylic square 
chamber (31.8 cm x 25.4 cm x 26.7 cm) with a electrifiable metal grids floor, a sound 
source, calibrated shock generator and video system (VFC system, Med Associates).  
The conditioning step consists in placing the mice in the chamber and allow 
them to explore the chamber for 180 seconds with a background sound. After that, a 
tone is presented as a conditioned stimulus, and a 0.5 mA footshock is given to the 
mice as an unconditioned stimulus during the last 2 seconds of the sound. The mice 
remained in the chamber for 30 seconds after the footshock.  
Twenty-four hours after the conditioning session, the mice are returned to the 
same conditioning chamber for 180 seconds for the contextual test in absence of the 
tone and the footshock. The freezing behavior (absence of motion excluding the 
respiration) was measured by video system (VFC system, Med Associates). The 
cued test was performed fallowing the context test. In this test, the mice were placed 
into a different context, smooth white floor that covered the metal grids and a curved 
white wall that covered the wall of the chamber. This provides a new context that is 
unrelated to the conditioning chamber. They were allowed to explore the chamber 
during 210 seconds and in the last 180 seconds was presented the auditory cue that 
at the time of conditioning was given to the mice. The freezing time was measured by 
video system (VFC system, Med Associates). The chambers were cleaned between 
mice in all tests.  
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IV. Results  
 
The present study analyses the function of PrPC in a mouse model with 5 
familial AD mutations. For this a novel bi-transgenic mice, Prnp0/05xFAD, exhibiting a 
gene knock out of Prnp (PrPC gene) was created. Different mice were stratified into 
four groups: 1) 5xFAD, 2) WT, 3) Prnp0/05xFAD and 4) Prnp0/0. Groups 1 and 2 
expressed the PrPC wild type gene on both alleles. To focus only on the Aβ induced 
toxicity in mice behaviour and not on a potential effect of a Prnp knockout, the group 
1 was compared with group 2 as well as group 3 was compared with group 4.  
A second aim is to investigate the Aβ induced toxicity during aging. For this 
reason we created three different aging groups: A young 3 month old group, a middle 
aged 9 month old group and an old age >12 months of age. 
 
 
1. Behavioural results 
 
1.1 Increase of life span in Prnp0/05xFAD mice 
To investigate the impact of PrPC on the life span of 5xFAD mice, the mice 
were housed under controlled temperature conditions (21-22°C) and had free access 
to food and water in a 12:12 h light: dark cycle. During a period of two years the 
survival of 5xFAD mice was monitored. Disease animals were excluded from 
statistical analysis.  
 
 
 
 
 
 
 
Figure 6. Determination of life span. During a period of two years we monitored the survival of 
5xFAD mice. Our data show that Prnp0/0 5xFAD mice have a longer average life span (more than 100 
days) than 5xFAD mice. We calculated the p values for statistical analyses. The number of stars 
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indicates the significance level: one star (*) for p<0.05, two (**) for p<0.01 and three (***) for p<0.001. 
Values are depicted as mean ± standard error of the mean.  
 
When we compared the life span of 5xFAD mice with Prnp0/05xFAD, we found 
that PrPC knockout mice (379,3 ± 50,11, n=6) had a longer life span (more than 100 
days) than 5xFAD mice (207,0 ± 26,38, n=8) (Figure 6). The t-test (p(0.05)= 0,0067) 
confirmed a significant influence of PrPC in  mice life span. 
 
 
1.2 Deficits in nest building behavior depend on 5xFAD mutation  
To assess the impact of 5xFAD mutation on nest building behavior, mice (3, 9 
and 12 month-old) were placed individually into a home cage with an untouched 
sheet of paper tissue (n=6 per group). The next day the quality of the nest was 
evaluated according to a five-point scale from Deacon et al (Deacon 2006). The 3 
months old groups (not shown) do not present significant variation in the nest quality 
among them (WT vs 5xFAD and Prnp0/0 vs Prnp0/05xFAD). 
 
 
 
 
 
 
 
Figure 7. Deficits in nest building behavior of 5xFAD mice.  The nest building behavior of WT vs 
5xFAD and Prnp0/0 vs. Prnp0/05xFAD mice was analyzed after placing a sheet of tissue paper into the 
cage overnight. The evaluation of nest quality revealed statistically significant differences into A and C 
groups. Graph B showed no significant difference among Prnp0/0 vs. Prnp0/05xFAD (9 months’ age). 
We calculated the p values and the number of stars indicates the significance level: one star (*) for 
p<0.05, two (**) for p<0.01 and three (***) for p<0.001. Values are depicted as mean ± SEM. Legend: 
(A) 9 months age, WT vs 5xFAD; (B) 9 months age, Prnp0/0 vs Prnp0/05xFAD; (C) 12 months age, 
Prnp0/0 vs Prnp0/05xFAD.  
 
 In 9 months groups (Figure 7), WT mice built a significantly better nest than 
5xFAD. Nevertheless, in 9 months age, Prnp0/0 mice built approximately equal nests 
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as the nests of Prnp0/05xFAD mice, statically there is no significant differences in the 
nest quality among these two groups. Interestingly, the evaluation of nests from 
Prnp0/05xFAD (12 months) had a significantly lower nest scores compared with 
respective control mice (Prnp0/0). The evaluation of the nest quality revealed a 
nesting score which is dependent from the 5xFAD mutations WT mice exhibited an 
average nesting score of 3, 5xFAD mice of 1.5, Prnp0/05xFAD mice of 1.2 and Prnp0/0 
mice of 1.5. The observed differences between Prnp0/05xFAD and Prnp0/0 are 
statistically significant after 12 months (Figure 7).  
 
 
1.3 PrPC-related changes in exploratory and locomotor behavior of 
5xFAD mice 
 In the first behaviour test, we examined the exploratory and locomotor 
behavior of our different mice groups (WT, 5XFAD, Prnp0/0 and Prnp0/05xFAD) by 
using the open field test (n=6 per group).  Mice groups at different ages (3, 9 and 12 
months) were allowed to explore a new environment in the open field test for 5 min. 
Behavioral measures include the total crossing times (locomotor activity and 
exploratory behavior) and time spent into central area (anxiety).  
Animals from all three months old groups exhibited a very similar locomotor 
activity and anxiety levels during the 5-min session (not shown), no significant 
differences were found among them. In 9 months old mice groups, WT mice 
exhibited higher locomotor activity than 5xFAD mice. The t-test (p< 0.05) reveals that 
differences are significant among WT and 5xFAD. Analyzing the data from Prnp0/0 
and Prnp0/05xFAD mice, we observe identical number of crossing times, Prnp0/0 mice 
(74,00 ± 10,24, n=6) and Prnp0/05xFAD mice (51,00 ± 16,54, n=6) showed no 
significant (p>0.05) locomotor activity. Considering the different areas of open-field, 
WT mice avoided the central area (high level of anxiety) and 5xFAD spent more time 
than WT into central area of the OF apparatus. 5xFAD exhibited less anxiety than 
WT and these results are statistically relevant (p<0.05). Interestingly, Prnp0/0 and 
Prnp0/05xFAD mice displayed identical anxiety levels between them (p>0.05). 
However, after 12 months of age, the t-test reveals statistical differences between 
Prnp0/0 and Prnp0/05xFAD in locomotor activity (p<0.05) and anxiety levels (p<0.05). 
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Prnp0/05xFAD crossed less times and had less anxiety levels compared with Prnp0/0. 
The significant results are shown in Figure 8.  
 
  
Figure 8. Determination of the exploratory behavior and locomotor activity using the open field 
test. The number of crossings as well as the activity of the animals in the central and peripheral 
squares were tallied. The evaluation of exploratory behavior and locomotor activity revealed 
statistically significant differences only in A and C groups. The relevant differences in anxiety-related 
behavior were found in B and D groups. We calculated the p values. The number of stars indicates the 
significance level: one star (*) for p<0.05, two (**) for p<0.01 and three (***) for p<0.001. Values are 
depicted as mean ± standard error of the mean. Legend: (A) locomotor activity, WT vs 5xFAD (9 
months age); (B) anxiety-related, Prnp0/0 vs Prnp0/05xFAD (12 months age); (C) locomotor activity 
behavior, WT vs 5xFAD (9 months age); (D) anxiety-related behavior, Prnp0/0 vs Prnp0/05xFAD (12 
months age). 
 
 
1.4 Object discrimination ability in 5xFAD mice   
 In the novel object recognition test mice learned to discriminate between a 
habituated (TF) and a novel object (TN). To investigate the impact of PrPC on object 
discrimination skills we subjected WT, 5xFAD, Prnp0/0 and Prnp0/05xFAD mice at 
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different ages (3, 9 and 12 months) to the NOR test (n=6 per group). The 
discrimination ability is indicated is by the  Recognition Index (RI), i.e., the time that 
mice spent to investigate the novel object relative to the total number of objects 
investigated [RI = TN/(TN + TF)].  
 The ability to recognize the new object was similar in all 3 months-old 
groups (not shown). At 9 months of age 5xFAD mice were less capable than WT 
mice to discriminate between the habituated object and the new one.  The t-test 
(p<0.05) confirmed significant differences in RI among WT and 5xFAD (Figure 9A). 
Data from Prnp0/0 and Prnp0/05xFAD (9 months) revealed that both groups were able 
to discriminate between a previously-encountered object and a novel object (p<0.05) 
(Figure. 9B). After 12 month of age (Figure 9C), in Prnp0/05xFAD mice the new object 
recognition capacity was decreased compared with Prnp0/0. This variation is 
statistically significant (p<0.05). 
 
Figure 9. Object discrimination skills. In the NOR test we measured the investigation time of the 
novel object in relation to the investigation of both objects (RI). Significant statistical differences were 
found in A and C groups. We calculated the p values and the number of stars indicates the 
significance level: one star (*) for p<0.05, two (**) for p<0.01 and three (***) for p<0.001. Values are 
depicted as mean ± standard error of the mean. Legend: (A) 9 months age, WT vs 5xFAD; (B) 9 
months age, Prnp0/0 vs Prnp0/05xFAD; (C) 12 months age, Prnp0/0 vs Prnp0/05xFAD.  
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1.5 Effect of PrPC level on the general anxiety behaviour of 5xFAD mice 
Elevated plus-maze task allowed us to analyze the general anxiety, which can 
be indicated by the time spent on the open arms. This test is based on the conflict 
between the natural desire of mice to explore a new environment and their fear of 
open and high spaces.  The more time mice spend into open arms less general 
anxiety they experience. 
 
Figure 10. Basal anxiety in 5xFAD mice is dependent on PrP level during aging. The elevated 
plus maze test revealed a decrease in general anxiety behavior (duration in open arms) in 9 months-
old 5xFAD mice compared to WT mice of the same age (A and B). No differences could be observed 
between Prnp0/05xFAD and Prnp0/0 mice after 9 months of age. After 12 months of age we observe 
that general anxiety decreased in Prnp0/05xFAD mice compared to Prnp0/0 controls without amyloid 
mutation (C and D). We calculated the p values. The number of stars indicates the significance level: 
one star (*) for p<0.05, two (**) for p<0.01 and three (***) for p<0.001. Values are depicted as mean ± 
standard error of the mean. Legend: (A) Mean time on open arms, WT vs 5xFAD (9 months age); (B) 
Mean time into closed arms, WT vs 5xFAD (9months age); (C) Mean time into closed arms, Prnp0/0 vs 
Prnp0/05xFAD (12 months’ age); (D) Mean time on open arms, Prnp0/0 vs Prnp0/05xFAD (12 months’ 
age). 
We used single exposure to the elevated plus maze to determine anxiety 
behavior of mice. The four groups (n=6 per group) were tested. Three month old 
mice showed similar anxiety levels (not shown). As illustrated in Figure 10, there is a 
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clear difference between mouse groups in general anxiety after 9 months age. Wild 
type group stayed longer in close arms (Figure 10A) and less time in open arms 
(Figure 10B) than 5xFAD. The t-test of time spent in closed arms was (p<0.01). The 
interpretation of these results reveals a less anxious behavior of 5xFAD mice 
compared to WT mice. Prnp0/0 and Prnp0/0 5xFAD (9 months showed no significant 
differences of anxious behavior between them. The t-test confirmed the similar 
behavior (p> 0.05) between Prnp0/0 and Prnp0/05xFAD, closed arms t-test and open 
arms t-test. Statistically significant results were observed among Prnp0/0 and 
Prnp0/05xFAD after 12 months of age. The Prnp0/0 spent less time than 
Prnp0/05xFAD in open arms (p<0.05). Prnp0/05xFAD had less anxiety than Prnp0/0 
(Figure 10C and 10D).  
 
 
 
1.6 Effect of PrPC level on motor performance of 5xFAD mice 
In experiment we assessed motor performance using the rotarod test. Motor 
performance was determined by measuring the time spent on the rotating rod (n=6 
per group). The 12-month-old groups were analyzed in a separate trial, in which the 
spinning of the rod was adapted to mouse age.  
  
 
 
 
 
 
 
 
Figure 11- Motor performance. In the rotarod task we determined the time, which the mice spent on 
the rotating rod. 5xFAD mice (9 months old) showed early motor impairment than 5xFAD Prnp0/0 (12 
months old). We calculated the p values. The number of stars indicates the significance level: one star 
(*) for p<0.05, two (**) for p<0.01 and three (***) for p<0.001. Values are depicted as mean ± standard 
error of the mean.   
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All 3 months of age groups exhibited a good performance and no motor 
significant differences were found between WT and 5xFAD or Prnp0/0 and 
Prnp0/05xFAD (not shown).Differences (p<0.01) started to appear between WT and 
5xFAD at 9 months, the WT group performed longer than 5xFAD, this means that 
WT had better motor skills than 5xFAD.The rotarod performance was  not 
significantly changed among Prnp0/0 and Prnp0/05xFAD (p>0.05). Differences 
occurred between Prnp0/0 and 5xFAD Prnp0/0 for older mice (12 months) (p<0.05). 
5xFAD Prnp0/0 mice were less capable to walk on rotarod compared with Prnp0/0. The 
statistical relevant results are presented in Figure 11. 
 
 
1.7 Effect of PrPC level on associated learning and memory skills of 
5xFAD mice 
To investigate the impact of PrPC level on the associative learning and 
memory skills of 5xFAD mice we subjected mice to the fear conditioning test. 
Freezing response will be demonstrated if the mouse remembers the environment 
with aversive stimulus. All mice were tested 24h later in the conditioning chamber for 
contextual learning (n=6 per group).  
Figure 12 - Contextual learning. Twenty-four hours after they received the footshock, the mice were 
monitored and it was quantified the freezing time. We calculated the p values. The t-test showed 
significant differences into 5xFAD (9 months old) mice group (A) and into Prnp0/05xFAD (12 months 
old) mice group (C). The number of stars indicates the significance level: one star (*) for p<0.05, two 
(**) for p<0.01 and three (***) for p<0.001. Values are depicted as mean ± standard error of the mean.  
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As expected, all 3 months old groups behaved in a similar manner (not 
shown), they were able to recognize the context of the aversive stimulus. In 
contextual test of the 9 months old groups, the t-test (p<0.05) showed significant 
differences between WT and 5xFAD. The majority of 5xFAD mice were not capable 
to link the context of the aversive stimulus (Figure 12A). In contrast, differences 
between Prnp0/0 and Prnp0/05xFAD freezing time was not statistically significant 
(Figure 12B), the performance was similar (p>0.05). The major differences (p<0.01) 
were observed among Prnp0/0 and Prnp0/05xFAD, the later ones showed a higher 
memory impairment compared with control group (Figure 12C). 
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2. Molecular results 
 
2.1 Effect of PrPC presence/absence on the Aβ production levels in 
5xFAD mice 
At first we examined the levels of Aβ1-40 and Aβ1-42 in the brain tissue of 
different mice groups (WT, 5xFAD, Prnp0/0 and Prnp0/05xFAD at different ages (3 and 
9 months) via ELISA (Figure.5). We found the levels of Aβ1-40 and Aβ1-42 was 
markedly increases in 5xFAD mice due to the familial AD mutations, independently 
from the expression of PrPC. During aging (between 3 and 9 months) both amyloid 
forms increased dramatically (more than 3 times). 
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Figure 13. Effect of PrPC level on the amount of Aβ1-40 and Aβ1-42 in transgenic mice. 
Concentrations of Aβ1-40 (6A and 6C) and Aβ1-42 (6B and 7D) were determined in WT, 5xFAD, Prnp0/0 
and Prnp0/05xFAD mice at an age of 3 and 9 months via IBL-ELISA. Levels of A1-40 and Aβ1-42 were 
increased after 9 months. For comparison between groups we used the student’s t-test (n=8 per group 
in three independent experiments). Error bars indicate standard deviation of the mean (SEM). One 
star (*) for p<0.05, two (**) for p<0.01, three (***) for p<0.001 and four (****) for p<0.0001. Values are 
depicted as mean ± standard error of the mean. 
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2.2 Immunohistochemical staining analysis of Aβ plaque deposits in 
5xFAD 
To investigate the impact of PrPC on the localization of Aβ plaques we 
performed an immuno staining of brain tissue derived from 9 months old mice. The 
figures show a diffuse distribution of Aβ plaques in the total brain tissues in both, 
5xFAD (Figure 7C) and Prnp0/05xFAD (Figure 7D). Control animals without 5xFAD 
mutation had no Aβ plaques in their brains (Figure 7A and 7B). No differences 
regarding the amount of Aβ deposits could be observed in both 5xFAD and 
Prnp0/05xFAD mouse lines (Fig. 7C and 7D). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 14. Immunohistochemical staining of Aβ plaque deposits in 9 month-old 5xFAD mice. 
DAPI-staining shows the dentate gyrus. No amyloid plaques were observed in WT (A) or Prnp0/0 (B). 
In 5xFAD (C) and Prnp0/05xFAD (D) mice the localization of plaques is diffuse all over the brain. The 
number of plaques was not significantly different in both 5xFAD mice groups (C and D). 
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2.3  Role of PrPC presence/absence in cell signaling  
To determine the role of PrPC in cell signaling we performed western blot 
analysis. We searched for Fyn, P-Fyn and Caveolin 1 expression from cortex of mice 
(9 months age).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 15. Western blotting from 9 months old groups (Fig. 15A) and relative quantification of 
bands (Fig. 15.B, 15C and 15D).The results from WB showed an increased amount of Fyn (Fig. 15B), 
P-Fyn (Fig.15C) and Caveolin 1 (Fig. 15D) in 5xFAD (wild type for PrPC) mice comparing to WT. 
SAF32 and APP confirmed the presence of PrPC expression and 5xFAD mutation, respectively. PrPC 
knockout with 5xFAD mutation (Prnp0/05xFAD mice) do not exhibit a different expression pattern of 
Fyn, P-Fyn and Caveolin 1 comparing to PrPC knockout without 5xFAD mutation (Prnp0/0) (Fig. 15.B, 
15C and 15D). SAF32 antibody was used to confirm the absence of PrPC in PrPC knockout group. 
APP antibody proved the 5xFAD mutation in PrPC knockout group (Prnp0/0 5xFAD). GAPDH antibody 
present the same protein amount in all samples, it means the differences seen in WB results are not 
due to different proteins amount (Fig.15A).  
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These proteins are known to be involved in Alzheimer disease pathway. 
5xFAD mice (9 months age) showed (Figure 15), as expected, an increased 
expression of Fyn, P-Fyn and Caveolin 1 comparing to WT mice. We did not noticed 
a different expression pattern of these three proteins in Prnp0/05xFAD comparing to 
Prnp0/0 and the expression of Fyn, P-Fyn and Caveolin 1 in Prnp0/05xFAD is nearly 
the same as in Prnp0/0. GAPDH antibody was used as loading control (protein 
amount), SAF-32 antibody was the control for PrPC expression (presence/absence) 
and APP antibody was used as a 5xFAD mutation control.  
 
 
3. Genotyping 
All mice were genotyped after birth by PCR. A biopsy from tail was used to 
check the genotype after sacrifice. Prnp+/+, Prnp0/0 and APP mutation (5xFAD) 
were analysed.The figure 16 shows the representative results from PCRs.  
 
 
 
 
 
 
 
 
Figure 16. Mice’s genotype. The image shows the positive and negative results for each genotype 
with their respective controls. 
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V. Discussion 
 
The major defined pathological hallmark of Alzheimer’s disease is the 
accumulation of amyloid beta, a neurotoxic peptide derived from beta and gamma-
secretase cleavage of the amyloid precursor protein. In this project we intend to 
investigate the role of the cellular prion protein (PrPC) in AD which is still 
contradictious. To clarify this issue we used two transgenic mice (5xFAD and 
Prnp0/05xFAD) by crossing PrPC knockout (Prnp0/0) mice (described by Büeler et 
al.(1992)) and 5xFAD mice exhibiting mutations in the APP and presenilin genes. 
The 5xFAD mice (Tg6799) genetic background C57Bl/6J,  have been previously 
described (Oakley et al. 2006). The 5xFAD mouse is one of a few known mouse 
models that exhibits significant neuron loss in addition of displaying other AD 
hallmarks such as amyloid plaques (Guglielmotto et al. 2012; Casas et al. 2004; 
Oakley et al. 2006). These mice express the 695 aminoacids isoform of the human 
amyloid precursor protein (APP695) carrying the Swedish/London/Florida mutations 
under the control of the murine Thy-1-promoter. In addition, human presenilin-1 
carrying the M146L/L286V mutations is expressed also under the control of the 
murine Thy-1-promoter. In these mice, the potential behavior changes at different 
ages by using a battery of standardized behaviour tasks was analysed. Moreover the 
progression of the amyloid pathology and the amount of Aβ in both mouse models 
were analysed in dependence of the PrPC expression via immunohistochemical 
staining and ELISA analysis. From these data we evaluated the potential of PrPC as 
a positive/negative key-player in AD and its potential as a therapeutic target. 
 
 
1. Role of PrPC in AD 
 
In addition to its protective function under oxidative stress conditions (Brown et 
al. 1997; Ramljak et al. 2015) increasing evidence suggest that PrP may play a role 
in Alzheimer’s disease or during the development of AD- pathology: 
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a) PrPC co-localizes with amyloid plaques (Schwarze-Eicker et al. 2005; 
Takahashi et al. 2011) which are present in CJD patients with amyloid 
pathology (Del Bo et al. 2006). 
b) The codon 129 methionine/valine polymorphism of the human PRNP 
influences the susceptibility to prion diseases. Furthermore, certain amino acid 
variations may also be a risk factor for early onset of AD (Dermaut et al. 2003; 
Riemenschneider et al. 2004) and the codon 129 polymorphism can modulate 
the number of amyloid deposits during cerebral aging (Berr et al. 2003). 
c) In disease models, clear evidence exists that PrPC is involved in the 
pathophysiological metabolism of APP. PrPC contains an amyloid oligomer 
binding site, a region within the central part of PrPC from amino acids 95-110 
(Laurén et al. 2009). PrPC thus may act as a potential receptor for Aβ 
mediating the toxicity of Aβ-oligomers.  
 
Nevertheless, three independent studies failed to confirm the postulated PrPC-
promoted toxic effects (Balducci et al. 2010) leaving the debate on the role of PrPC 
still open.  
 
 
2. Influence of PrPC on Aβ production 
 
Aβ is formed during the amyloidogenic pathway of APP processing by 
cleavage of APP by two secretases, the beta-secretase and the gamma-secretase. 
Recent studies on AD models indicated a causal involvement of PrPC in the amyloid 
pathogenesis of AD.  An in vitro study indicated that PrPC may influence the 
processing of APP by inhibition of BACE1 (Parkin et al. 2007) and it was proposed 
that one of the physiological functions of PrPC may be the regulation of the β-
secretase activity. 
To investigate the role of PrPC on the processing of APP we examined the 
expression of Aβ1-40 and Aβ1-42 in brain tissue of different mice groups (WT, 
5xFADWT, Prnp0/0 and Prnp0/05xFAD) at different ages (3, 9 and 12 months) via 
ELISA. We found that levels of Aβ1-40 and Aβ1-42 was, as expected, dramatically up-
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regulated in 5xFAD mice independently from PrPC. During aging process (between 3 
and 9 months) levels of both amyloid forms increased markedly, which are induced 
by the familial AD mutations.  When we compared the amount of Aβ in 5xFAD and 
Prnp0/05xFAD, we found a significant increase of Aβ1-40 but not the pathogenic form, 
Aβ1-42, in Prnp0/05xFAD. Our results suggest that PrPC may influence Aβ1-40 amount 
but, apparently, it does not influence the Aβ1-42 generation. Our findings agree in part 
with a previous in vitro study describing that PrPC affects Aβ levels by decreasing the 
cleavage of APP by BACE1. PrPC can influence the processing of APP and the 
amount of APP-cleavage products Aβ1-40 and Aβ1-42, while the expression of APP and 
β-secretase remained unchanged, which is in line with others authors (Gimbel et al. 
2010; Parkin et al. 2007). 
 One explanation for the selective regulation of Aβ1-40 but not of Aβ1-42 via PrPC 
may be that APP metabolism is more complex, e.g. APP can be processed by 
different pathways. Not all were influenced by PrPC. Another possibility is via protein 
binding. Previous studies revealed that PrPC can potentially interact with APP and 
BACE. While PrPC interaction with the pro-domain of an immature Golgi-associated 
form of BACE1 may restrain BACE1 in the trans-Golgi network, (Gimbel et al. 2010), 
PrPC might additionally influence the APP cleavage via binding to APP/sAPP 
(Schmitz et al., 2014). This inhibition might be explained by conformational changes 
within full-length APP which may, at least partly, bury the binding epitope of PrPC 
(Schmitz et al., 2014).  
Altogether, the fact that PrPC reduces the amount of cell-toxic Aβ1-40 but not 
Aβ1-42 may indicate that PrPC may have a neuroprotective function in AD. To 
elucidate the potential role of PrP in AD further studies on the interaction of PrP an 
Aβ and on the influence of PrP on the Aβ induced toxicity were undertaken. 
 
 
3. Cellular prion protein do not influence the distribution of β-amyloid 
deposition in 5xFAD mice 
Amyloid plaques, deposits of the Aβ peptide (Glenner & Wong 1984), are 
defining lesions in AD brain. β-secretase has been implicated in amyloid production 
and plaque formation (Cai et al. 2012), and its activity is directly related to Aβ load 
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(Capetillo-Zarate et al. 2012; Ho et al. 2005). Additionally, it has been proposed that 
PrPC expression may decrease plaque formation (Chung et al. 2010). We performed 
an immunohistochemical staining of Aβ deposits in brains derived from 5xFAD and 
Prnp0/05xFAD mice. We showed in both mice models a diffuse distribution of Aβ 
deposits, whose amount is increased during the aging process. However, a 
comparison of the distribution and number of Aβ deposits revealed no significant 
differences between both mice models. Several authors have proposed that APP is 
cleaved by BACE1, and BACE1 is inhibited by PrPC, wherefore the absence of PrPC 
should promote an increase in Aβ production, supporting a relationship between 
BACE1 and PrPC (Kellett & Hooper 2009; Parkin et al. 2007). However, most of these 
studies were performed in cell culture. A study performed in an AD mouse model, 
indicated that the deletion of PrPC did not affect APP or Aβ deposition (Griffiths et al. 
2011). According to our results, it may be speculated that instead basal amyloid 
levels are modified, secondary events associated with alternative production of 
amyloid and/or degradation events influence Aβ deposition (Ordóñez-Gutiérrez et al. 
2013), for instance, disruption of lysosomal proteolysis and autophagy has been 
described in response to Presenilin 1 mutation. Beyond what was previously 
described, it has been suggested that Aβ undergo phosphorylation. The 
phosphorylation may lead the conformational transition and formation of toxic 
aggregates. Additionally, phosphorylated Aβ seems to be resistant against 
degradation by proteases (Kumar & Walter 2011). 
 
4. Prnp0/05xFAD mice exhibited a longer life span and a delayed occurrence 
of behavioral deficits  
Alzheimer's disease is characterized by a deficit in motor and spatial learning–
memory and alteration of non-cognitive behavior. Lauren et al. (2009), found that Aβ 
oligomers inhibit long-term potentiation (LTP) in hippocampal slices from normal 
mice, but not in hippocampal slices from mice lacking PrPC. LTP provides a measure 
of synaptic plasticity related to learning and memory, these two skills are 
compromised in Alzheimer’s disease. As mentioned before, our intention is to rule 
out PrPC related effects in our behavior study (analyzed before by Schmitz et al., 
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2014) and to focus on Aβ-induced deficits in mice solely. We analyzed 5xFAD mice 
in comparison to WT and compared Prnp0/05xFADmice to Prnp0/0 animals. To 
understand the role of PrPC in AD we monitored the survival of animals over a 2 
years period and we used a panel of different behavioral tests (motor function, 
general anxiety behavior, and cognition) to assess the onset and progression of Aβ-
induced deficits, in presence/absence of PrPC. 
Basal anxiety and exploratory behavior in mice were investigated using the 
EPM and open field tests, respectively. The basal anxiety was significantly reduced 
paired with a decreased locomotion and exploration in 5xFAD mice compared to WT 
animals at 9 months of age. In the literature, anxiety-related behavior has been 
demonstrated to be reduced in different AD mice models (Jawhar et al. 2012; 
Lalonde et al. 2003; Faure et al. 2011). The impairment may be interpreted in many 
ways, for instance, a loss in motivation to explore, inhibitory control or spatial 
orientation (Lalonde 2002), similar to symptoms described in Alzheimer dementia 
(Chung & Cummings 2000; Frisoni et al. 1999; Daffner et al. 1992).  Interestingly, in 
absence of PrPC, the behavior of the mice (Prnp0/05xFAD 9 months old) seems to be 
not affected by the high levels of β amyloid. Although later (12 months old) Prnp0/0 
5xFAD mice showed a decreased anxiety and less locomotor activity when 
compared with Prnp0/0 12 months old group. Similar results were found in learning 
and memory tests. To investigate learning and memory deficits, the cardinal 
symptoms of AD, we performed the Fear Conditioning and NOR tests. We 
demonstrated significant memory deficits in 9 months old 5xFAD mice. Our results 
are in agreement with several studies demonstrating reduced working memory levels 
that decline with age in several of AD models (Chapman et al. 1999; Lovasic et al. 
2005; Duyckaerts et al. 2008; Wirths et al. 2008). A similar impairment was found in 
our results (in 5xFAD Prnp0/0 12 months old mice). Both results suggest a decline of 
associative learning and memory. It has been postulated that the decline of memory 
function begins around 6 months of age in 5xFAD mice (Devi & Ohno 2010). 
However, these deficits were not observed until 12 months old in Prnp0/05xFAD mice. 
We used rotarod performance which requires postural adjustments for the 
maintenance of equilibrium on a rotating and accelerating rod. We observed an age-
dependent decrease in motor function only at 9 month old in 5xFAD mice and at 12 
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months old in Prnp0/05xFAD. Prnp0/05xFAD (12 months of age) showed less ability to 
performed rotarod test when compared to their controls. The ability to perform the 
rotarod task cannot be attributed to a single brain region, it has been shown to be a 
sensitive indicator of cerebellar abnormalities, for example cerebellar cortex, deep 
cerebellar nuclei, dysfunction and/or neuronal loss (Hilber & Caston 2001).  
The nest provides them, among other things, shelter, heat conservation and 
reproduction. It is essential for long lifetime and reproductive success of mice (Bult & 
Lynch 1997). 5xFAD 9 months old mice were less capable and less motivated to 
build their nest when compared with the same age wild type group, resulting in very 
poorly shredded, almost untouched material. Poor nest build was reported in other 
mice with AD mutations (Filali et al. 2009; Deacon et al. 2008).  Nesting behavior is 
reduced along age, paralleling with increase of Aβ burden with age (Min et al. 2013). 
However, it seems that this tendency is quite retarded in Prnp0/05xFAD. Our results 
show that the deficits found in 5xFAD mice (9 months) are delayed in Prnp0/05xFAD, 
since for the later these deficits only appear at 12 months age.  
Alongside behavioral tests we recorded the mortality of the mice. Interestingly, 
the analysis 5xFAD exhibited a significant shorter life span (almost 50% less) than 
Prnp0/05xFAD mice, indicating a clear effect of PrPC on the survival of 5xFAD mice. 
Due to this reason, we have not tested any group more than 12 months. 
Overall, as expected, in all behavioral tests the 5xFAD mice showed a 
significant decrease of their performance potential due to Aβ toxicity. Aβ peptide is 
formed extracellularly and to induce toxicity it is necessary that the toxic signal pass 
through the membrane. PrPC has been suggested as a Aβ receptor inducing Aβ 
toxicity into cell (Laurén et al. 2009). This hypothesis may explain the decrease of 
performance in 5xFAD mice during aging. Although, in the absence of PrPC 
(Prnp0/05xFAD mice), deficiencies also appear, they are delayed. The delayed 
impairments might be due to the presence of other receptors for Aβ besides PrPC. 
Other proteins have been described as “Aβ receptors”, for instance, N-methyl-D-
aspartate receptors (NMDARs), glycation end products (RAGE), α7-nicotinic 
acetylcholine receptor (α7 nAChR), ephrin type B receptor 2, immunoglobulin G Fc 
gamma receptor IIb (FcγRIIb), and paired immunoglobulin-like receptor B (PirB) 
(reviewed in Kam, Gwon and Jung, 2014). Undoubtedly, PrPC may play a main role in 
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inducing Aβ neurotoxicity, but it seems not to be the only one. In the absence of PrPC, 
it may be required a greater amount of Aβ for the manifestation of the disease.  
  
 
5. Regulation of downstream signaling proteins via PrPC inducing the 
toxicity of Aβ 
It was suggested that PrPC mediates the toxic effect of Aβ oligomers and is 
required for Aβ oligomer-induced suppression of synaptic plasticity, synapse 
damage, and neuronal cell death (Laurén et al. 2009; Bate & Williams 2011). Several 
reports  showed  that oligomeric amyloid-β binds to residues 23-27 and 95-110 of 
PrPC, which underlines the relevance of PrPC in AD (Chen et al. 2010; Zou et al. 
2011; Fluharty et al. 2013; Younan et al. 2013). This binding results in activation of 
the Fyn kinase (Um et al. 2012). Fyn belongs to the family of Src kinases which are 
generally involved in signal transduction events (Toni et al. 2006). Activation of Fyn 
by the Aβ–PrPC complexes also leads to abnormal hyperphosphorylation of Tau. Fyn 
activity, like that of other Src family kinases, is regulated by intramolecular 
interactions that depend on the equilibrium between tyrosine phosphorylation and 
dephosphorylation (Figure 17).  Our western blot analysis (from 9 months old mice) 
revealed an up-regulation of Fyn and P-Fyn levels (in mice with AD mutation), due to 
the presence of PrPC, since in the absence of PrPC (Prnp0/05xFAD mice) there is no 
up-regulation of both proteins when compared with Pnrp0/0. Our results, are in 
accordance with a previous study which demonstrated that PrPC may promote Fyn 
activation when PrPC bound to Aβ (Laurén et al. 2009). Although, PrPC (mostly 
extracellular protein) and Fyn (intracellular protein) are differentially located  within 
cells which prevents a direct physical contact (Um et al. 2012), the physiological 
connection of both proteins suggest the involvement of other signaling proteins 
(Figure 16).  
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Figure 17. Scheme illustrating the recently reported data on, PrPC and Aβ oligomer removal. (1) 
Normal trafficking of the PrPC from lipid rafts into the cell his mediated by Cu2+ and a co-receptor 
(Taylor & Hooper 2007). Interaction with Aβ oligomers (2) may modify the interaction of PrPC with its 
co-receptor leading to a putative endocytic process (3) (Laurén et al. 2009). However, whether this 
process takes place and Aβ oligomers are degraded or whether it modifies signal transduction as 
indicated warrant further study. In addition, a link between these interactions and tau phosphorylation 
is missing. Lastly, a putative interaction of PrPC with Aβ oligomers to enhance fibril formation and Aβ 
deposition could take place (4). (Nicolas et al. 2009) 
 
Caveolae are specialized membrane microdomains that contain members of 
the caveolin protein family. They are enriched in cholesterol and glycosphingolipids 
and often appear as flask-shaped invaginations in the plasma membrane (Parton, 
2003). It has been observed that PrPC is mainly localized in caveolae membrane 
domains of neuronal cells (Massimino et al. 2002). It was confirmed that PrPC is 
internalized by caveolae (Peters et al. 2003), facilitating internalization of Aβ 
oligomers into intracellular compartments (Figure 18). The obtained data revealed an 
up-regulation of Caveolin-1 (Cav-1) in 5xFAD mice in comparison to wild type mice. 
This up-regulation in AD was ascribed to alteration in membrane properties of brain 
cells. AD brain have a narrower membrane than normal brain (Gaudreault et al. 
2004). Our observation that Prnp0/05xFAD mice did not exhibit up-regulated Cav-1 
levels, suggests that regulation of Cav-1 levels is dependent on PrPC concentration. 
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Figure 18. Proposed model of tau regulation by the triad Aβ-PrPC-Fyn. In the presence of 
accumulating Aβ, PrPC, Fyn and Cav-1 form a complex at the plasma membrane. Upon 
phosphorylation of Fyn at Y416, this complex becomes biologically active. Two scenarios are possible 
depending on the status of Fyn with respect to tau: (a), activated Fyn causes the 
hyperphosphorylation of tau at Y18 and its aberrant accumulation at the postsynaptic density (PSD). 
In the model (b), Fyn is already bound to tau in the dendrite, translocate to the PSD to interact with 
PSD95. There, Fyn could be phosphorylated, resulting in Fyn activation and tau phosphorylation at 
Y18. Adapted from: (Larson et al. 2012) 
 
Excessive activation of NMDARs has also been implicated in AD by 
engagement of an Aβ/PrPC/Fyn pathway (Paoletti et al. 2013). NMDAR hyperactivity 
leads to excessive Ca2+ influx through NMDARs, ultimately leading to neuronal 
death. Therefore, it seems that PrPC is crucial for cell damage by Aβ toxicity.  
Altogether, we did not found in Prnp0/05xFAD mice the up-regulation of P-Fyn, 
Fyn or Cav-1 as we found in 5xFAD mice. This suggests an important role of PrPC in 
Alzheimer’s disease as a promoter of toxic effect of Aβ oligomers. The presence of 
PrPC seems to have a whole set of circumstances that promote the toxicity of Aβ 
oligomers, for instance, overregulation of Fyn that is thought to be responsible for Aβ 
toxicity. However, this does not mean that absence of PrPC can completely prevent 
the Aβ induced toxicity in cells. These results are still preliminary, more research is 
required. 
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VI. Conclusion 
 
Alzheimer’s disease is a progressive neurodegenerative disorder that affects 
millions of people worldwide, although currently has no effective treatment options. It 
is urgent to know the mechanisms of disease and potential treatments. PrPC was 
suggested as a potential target for the treatment of AD due to its important role in the 
disease. Our study indicated a regulatory effect of the PrPC level on the processing of 
APP. Investigating the amount of amyloid beta in 5xFAD mice we observed a PrPC 
dependent regulation in 9 month-old animals of Aβ1−40 but not of the toxic form 
Aβ1−42. The behaviour study revealed significant deficits in general anxiety, learning 
performance and motoric function in 5xFAD mice, which correlate with the increase 
of amyloid beta mediated toxicity during the aging process of 5xFAD mice. 
Interestingly, behavioural deficits occurred earlier (after 9 months) in 5xFAD mice 
than in Prnp0/05xFAD (after 12 months) mice indicating that PrPC may accelerate the 
amyloid beta-induced toxicity. Our data support a role of PrPC as accelerator in AD 
mediating the toxicity of Aβ. In this sense, we can conclude, although does not avoid 
the disease, PrPC may be used as a first approach to delay the symptomatic effects 
of AD.  
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